Investment ThemesDetailed Quotes
CAR-T Therapy
Watchlist
- 1036.495
- +7.915+0.77%
Trading Jul 16 10:33 ET
1039.491High1026.717Low
1028.758Open1028.580Pre Close12.10MVolume9Rise16.44P/E (Static)583.42MTurnover--Flatline0.08%Turnover Ratio1.12TMarket Cap1Fall1.10TFloat Cap
Constituent Stocks: 10Top Rising: VCEL+2.72%
Sign in to post a comment
$bluebird bio(BLUE.US$ sad sold early 🫠
1
3
$bluebird bio(BLUE.US$
till one day we need this kind of service, it may reach the roof 😂
but dont know when will it be
till one day we need this kind of service, it may reach the roof 😂
but dont know when will it be
The earnings season is picking up speed, and this mid-July, we're about to get updates from some of the biggest names across various industries. Expect to hear from large banks, healthcare companies, airlines, and some of the tech and telecom giants that we all know.
The season started off last Friday with $JPMorgan(JPM.US$ , $Wells Fargo & Co(WFC.US$ , and $Wells Fargo & Co(WFC.US$ sharing their numbers. They all did bett...
The season started off last Friday with $JPMorgan(JPM.US$ , $Wells Fargo & Co(WFC.US$ , and $Wells Fargo & Co(WFC.US$ sharing their numbers. They all did bett...
+3
19
A flood of earnings will be coming over the next three weeks. This week will feature mostly financial companies.
Monday: Goldman Sachs ( $Goldman Sachs(GS.US$ ) and money manager Blackrock ( $Blackrock(BLK.US$ )
Tuesday: Health-insurer UnitedHealth Group ( $UnitedHealth(UNH.US$ ) , Bank of America ( $Bank of America(BAC.US$ ) , Morgan Stanley ( $Morgan Stanley(MS.US$ ) and Charles Schwab ( $Charles Schwab(SCHW.US$ ) .
Wednesday: Chip-equipment maker ASML ( $ASML Holding(ASML.US$ ) , pharm...
Monday: Goldman Sachs ( $Goldman Sachs(GS.US$ ) and money manager Blackrock ( $Blackrock(BLK.US$ )
Tuesday: Health-insurer UnitedHealth Group ( $UnitedHealth(UNH.US$ ) , Bank of America ( $Bank of America(BAC.US$ ) , Morgan Stanley ( $Morgan Stanley(MS.US$ ) and Charles Schwab ( $Charles Schwab(SCHW.US$ ) .
Wednesday: Chip-equipment maker ASML ( $ASML Holding(ASML.US$ ) , pharm...
1
Earnings in the week ahead could be the next catalyst for a broadening market
$Johnson & Johnson(JNJ.US$ is expected to announce its fiscal Q2 earnings before the markets open on Wednesday, July 17.
Ahead of the event, analysts expect Johnson & Johnson to report a profit of $2.73 per share, down 2.5% from $2.80 per share reported in the year-ago quarter. The company has consistently surpassed Wall Street...
$Johnson & Johnson(JNJ.US$ is expected to announce its fiscal Q2 earnings before the markets open on Wednesday, July 17.
Ahead of the event, analysts expect Johnson & Johnson to report a profit of $2.73 per share, down 2.5% from $2.80 per share reported in the year-ago quarter. The company has consistently surpassed Wall Street...
29
1
ColumnsWhat to Expect in the Week Ahead (GS, JNJ, TSM, and NFLX Earnings; Retail Sales and Housing Starts)
Earnings in the week ahead could be the next catalyst for a broadening market
$Johnson & Johnson(JNJ.US$ is expected to announce its fiscal Q2 earnings before the markets open on Wednesday, July 17.
Ahead of the event, analysts expect Johnson & Johnson to report a profit of $2.73 per share, down 2.5% from $2.80 per share reported in the year-ago quarter. The company has consistently surpassed Wall...
$Johnson & Johnson(JNJ.US$ is expected to announce its fiscal Q2 earnings before the markets open on Wednesday, July 17.
Ahead of the event, analysts expect Johnson & Johnson to report a profit of $2.73 per share, down 2.5% from $2.80 per share reported in the year-ago quarter. The company has consistently surpassed Wall...
+3
114
16
Why do you think $Pfizer(PFE.US$ decided to progress with Danuglipron? (![]()
Can't give up this huge market?
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
The P2 data they published in obese, non-diabetics doesn't look too good. Danuglipron twice daily compared with $Eli Lilly and Co(LLY.US$ Orforglipron and $Structure Therapeutics(GPCR.US$ GSBR 1290 at week 12: Orforglipron seems to be the best non-peptide GLP-1 RA
+1
5
No comment yet
thedioyears : What price? and how many?
ETONAOP : 1.25
not much hehe
now waiting for the dip
thedioyears ETONAOP: Not bad lol you'll be able to buy back in lol. Seen this too many times